Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 138.01 USD 1.2%
Market Cap: 8.2B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Ascendis Pharma A/S
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ascendis Pharma A/S
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
Net Income (Common)
-€426.5m
CAGR 3-Years
-1%
CAGR 5-Years
-20%
CAGR 10-Years
-68%
Genmab A/S
CSE:GMAB
Net Income (Common)
kr5.5B
CAGR 3-Years
30%
CAGR 5-Years
36%
CAGR 10-Years
45%
Zealand Pharma A/S
CSE:ZEAL
Net Income (Common)
-kr1.1B
CAGR 3-Years
2%
CAGR 5-Years
-16%
CAGR 10-Years
-37%
B
Bavarian Nordic A/S
CSE:BAVA
Net Income (Common)
kr707.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Net Income (Common)
-kr50m
CAGR 3-Years
6%
CAGR 5-Years
0%
CAGR 10-Years
-10%
Saniona AB
STO:SANION
Net Income (Common)
-kr81.8m
CAGR 3-Years
39%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
No Stocks Found

Ascendis Pharma A/S
Glance View

Market Cap
8.4B USD
Industry
Biotechnology

Ascendis Pharma A/S has established itself as a dynamic force within the biotechnology sphere, driven by a patented technology platform designed to address unmet medical needs. Founded in 2006 and headquartered in Denmark, the company has honed its focus on developing therapies to improve patients' lives by addressing significant health conditions, primarily in the fields of endocrinology and oncology. At the heart of its strategy is the TransCon technology, which revolves around prodrug methodologies that release active drug molecules at controlled rates, enhancing efficacy and reducing side effects. This platform allows Ascendis to develop extended-release versions of existing drugs, ensuring a more sustained therapeutic effect. Financially, Ascendis generates revenue by forging strategic partnerships and licensing agreements, enabling it to share in the commercialization success of its innovative pipeline products. By collaborating with larger pharmaceutical firms, Ascendis scales its impact, leveraging shared resources and expertise to bring its specialized treatments to market. Moreover, as its pipeline matures, it seeks to capitalize on successful clinical trials by moving products into commercial phases, which can result in additional income streams from direct product sales. The journey of Ascendis Pharma is emblematic of its commitment to innovation, sustainability, and delivering tangible healthcare advances through its robust technology-driven approach.

ASND Intrinsic Value
168.55 USD
Undervaluation 18%
Intrinsic Value
Price

See Also

What is Ascendis Pharma A/S's Net Income (Common)?
Net Income (Common)
-426.5m EUR

Based on the financial report for Sep 30, 2024, Ascendis Pharma A/S's Net Income (Common) amounts to -426.5m EUR.

What is Ascendis Pharma A/S's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-68%

Over the last year, the Net Income (Common) growth was 29%. The average annual Net Income (Common) growth rates for Ascendis Pharma A/S have been -1% over the past three years , -20% over the past five years , and -68% over the past ten years .

Back to Top